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Abstract 
 
The cellular energy sensor AMP-activated 
protein kinase (AMPK) is a metabolic 
regulator that mediates adaptation to 
nutritional variations in order to maintain a 
proper energy balance in cells. We show here 
that suckling-weaning and fasting-refeeding 
transitions in rodents are associated with 
changes in AMPK activation and the cellular 
energy state in the liver. These nutritional 
transitions were characterized by a metabolic 
switch from lipid to glucose utilization, 
orchestrated by modifications in glucose levels 
and the glucagon:insulin ratio in the 
bloodstream. We therefore investigated the 
respective roles of glucose and pancreatic 
hormones on AMPK activation in mouse 
primary hepatocytes. We found that glucose 
starvation transiently activates AMPK, 
whereas changes in glucagon and insulin levels 
had no impact on AMPK. Challenge of 
hepatocytes with metformin-induced metabolic 
stress strengthened both AMPK activation and 
cellular energy depletion limited-glucose 
conditions, whereas neither glucagon nor 
insulin altered AMPK activation. Although 
both insulin and glucagon induced AMPK! 
phosphorylation at its Ser-485/491 residue, 
they did not affect its activity. Finally, the 
decrease in cellular ATP levels in response to 
an energy stress was additionally exacerbated 
under fasting conditions and by AMPK 
deficiency in hepatocytes, revealing metabolic 
inflexibility and emphasizing the importance 
of AMPK for maintaining hepatic energy 
charge. Our results suggest that nutritional 
changes (i.e. glucose availability), rather than 
the related hormonal changes (i.e. the 
glucagon:insulin ratio), sensitize AMPK 
activation to the energetic stress induced by the 
dietary transition during fasting. This effect is 
critical for preserving the cellular energy state 
in the liver. 
 
 
Introduction 
 
AMP-activated protein kinase (AMPK) is a 
major energy sensor that regulates cellular and 
whole-body energy homeostasis (1). It is 
widely accepted that AMPK integrates 
nutritional and hormonal signals to maintain 
the cellular energy balance and execute 
appropriate metabolic functions (e.g., 
inhibition of ATP-consuming pathways and 
promotion of ATP-generating pathways) in 
response to nutritional environmental 
challenges. AMPK is activated in response to a 
variety of metabolic stresses or hormonal 
changes that typically change the cellular 
AMP/ATP and ADP/ATP ratios caused by 
increasing ATP consumption or reducing ATP 
production, such as that observed following 
starvation, exercise, hypoxia, ischemia, or 
inhibition of mitochondrial oxidative 
phosphorylation. 
AMPK is a heterotrimeric complex 
consisting of a catalytic ! subunit and two 
regulatory subunits, " and #. Each subunit has 
at least two isoforms. The !-subunit contains 
the kinase domain, which is normally active 
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only when a critical residue, Thr172, is 
phosphorylated within the activation loop (2). 
The upstream kinases that phosphorylate this 
site have been identified as the tumor 
suppressor liver kinase B1 (LKB1) and 
Ca2+/calmodulin-activated protein kinase 
(CaMKK2). While Thr172 residue represents 
the major AMPK phosphorylation and 
activation site in the !-subunit, 
phosphorylation of some Ser/Thr residues 
within the ST loop by PKA, Akt, and GSK3, 
associated with reduced !-Thr172 
phosphorylation, has been reported to inhibit 
AMPK activity (1,3). The  !-subunit acts as a 
scaffold to link the three subunits and contains 
a myristoylation site that is important for the 
subcellular localization and activation of 
AMPK (4-6). The "-subunit contains four 
tandem repeats of the cystathionine #-synthase 
(CBS) motif, which provides binding sites for 
the regulatory nucleotides, AMP, ADP, and 
ATP. 
Binding of AMP or ADP activates AMPK 
by various mechanisms that are all inhibited by 
ATP. They include the promotion of AMPK !-
subunit Thr172 phosphorylation by the 
upstream kinase LKB1 and inhibition of !-
Thr172 dephosphorylation by protein 
phosphatases. In addition, binding of AMP, but 
not ADP, causes allosteric activation of up to 
10-fold. Activation of AMPK can also occur 
independently of AMP/ADP binding through 
!-Thr172 phosphorylation by CaMKK2 in 
response to increased intracellular Ca2+ levels. 
An additional AMP/ADP-independent 
mechanism is engaged upon glucose removal 
by the formation of an axin/LKB1/AMPK 
complex at the surface of lysosomes, leading 
to the phosphorylation and activation of a 
compartmentalized pool of AMPK. The 
activation of distinct subcellular pools of 
AMPK may play an important role in the 
phosphorylation of specific downstream 
targets. Indeed, a recent study reported that the 
intensity of stress stimulation triggers 
differential AMPK activation in the lysosomal, 
cytosolic, and mitochondrial fractions to target 
specific metabolic pathways, depending on the 
metabolic status of the cell (7). 
In the liver, AMPK plays a crucial role in 
the regulation of lipid partitioning between 
oxidative and biosynthetic pathways through 
the phosphorylation and inactivation of its 
well-established targets, acetyl-CoA 
carboxylase (ACC) 1/2 at Ser79/Ser212 
residue and 3-hydroxy-3-methylglutaryl 
(HMG) coenzyme A (CoA) reductase 
(HMGCR) at Ser871 residue (8-12). The 
transition from the fasting to refed state is 
associated with modifications in hepatic lipid 
metabolism (i.e., increased fatty-acid synthesis 
and decreased fatty-acid oxidation) that appear 
to coincide with changes in the activation and 
phosphorylation of the AMPK !-subunit at 
Thr172 and ACC at Ser79 (13-16). This 
observation raises the possibility that the 
modulation of AMPK activity may contribute 
to the shift of lipid metabolism in the liver 
from catabolism to anabolism. However, the 
specific cues that mediate such changes in 
AMPK signaling are still poorly understood. 
The hepatic metabolic adaptations that occur 
during fasting/refeeding are primarily triggered 
by changes in the glucagon/insulin ratio. 
During fasting, plasma glucagon levels are 
high and plasma insulin and glucose levels are 
low. By contrast, refeeding increases plasma 
glucose and insulin concentrations. Hence, 
changes in glucose availability and/or the level 
of pancreatic hormones may directly modulate 
hepatic AMPK activity during this metabolic 
transition. AMPK activity during fasting and 
refeeding may thus be regulated by glucagon 
or insulin-stimulated changes in kinase 
phosphorylation, respectively (15,17,18). 
Consistent with this possibility, the AMPK "-
subunit is phosphorylated at multiple sites, 
including "1-Ser485/"2-Ser491, by the 
insulin-activated protein kinase Akt, inhibiting 
subsequent phosphorylation of !-Thr172 by 
upstream kinases (19,20). 
Here, we provide evidence that hepatic 
AMPK activity is insensitive to changes in 
insulin and glucagon levels but is instead 
sensitive to variations in glucose availability. 
Such regulation is central to defining the 
threshold of AMPK activation during 
metabolic/energy stress in the liver. 
 
Results 
 
Nutritional transition is associated with 
changes in AMPK activation and the energy 
state in the liver 
The suckling-weaning transition is 
accompanied by marked changes in metabolic 
pathways in the liver (i.e., a metabolic switch 
from lipid to glucose utilization with a 
decrease in lipid oxidation and an increase in 
glycolysis and lipogenesis) (21). During the 
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suckling period, the plasma insulin 
concentration is low and that of glucagon high 
because of the ingestion of milk, which is a 
high-fat, low-carbohydrate food. The transition 
from a milk diet to a high-carbohydrate diet at 
weaning leads to an increase in blood glucose 
and plasma insulin levels (Fig. 1A). Weaning 
from maternal milk was associated with a 
decrease in the phosphorylation of AMPK at !-
Thr172 and that of its substrate ACC at Ser79 
in the liver, whereas the abundance of the 
AMPK and ACC proteins was unchanged (Fig. 
1B). In this context, increased phosphorylation 
of Akt at Ser473 reflects activation of the 
insulin-signaling pathway (Fig. 1B). 
Conversely, AMPK signaling was highly 
active in the liver of suckling rats, as 
characterized by an increase in the 
phosphorylation of AMPK-!-Thr172 and 
ACC-Ser79 (Fig. 1B). 
As expected, the transition from fasting to 
refeeding was associated with an increase in 
blood glucose and insulin levels and a decrease 
in blood glucagon levels (Fig. 1C). In the liver 
of starved mice, phosphorylation of AMPK-!-
Thr172 and ACC-Ser79 was markedly higher 
than that of refed mice (Fig. 1D), in agreement 
with previous studies (13-16). Conversely, the 
increase in blood insulin levels in refed mice 
induced the phosphorylation of Akt at Ser473 
residue (Fig. 1D). During fasting, changes in 
AMPK activation were associated with a lower 
cellular energy state, as revealed by the 
decrease and increase of hepatic ATP and ADP 
concentrations, respectively, resulting in a 
significant increase in the ADP/ATP ratio (Fig. 
2). Thus, hepatic AMPK activation induced by 
fasting is associated with a decrease in the 
cellular energy state in the liver. 
 
AMPK deficiency exacerbates cellular energy 
depletion in response to metabolic stress in 
the liver 
AMPK plays a crucial role in maintaining 
energy homeostasis during periods of 
metabolic stress. We therefore hypothesized 
that AMPK deficiency in the liver may alter 
sensitivity to an energy stress. We tested this 
hypothesis by treating hepatic AMPK-deficient 
mice with metformin, a mitochondrial 
respiratory chain inhibitor (22,23). Metformin 
treatment induced a marked increase in the 
ADP/ATP ratio in the livers of control 
animals. Importantly, the increase in the 
ADP/ATP ratio was greater in AMPK-
deficient liver (Fig. 3A and 3B). In agreement 
with the inhibitory action of metformin on 
mitochondrial complex 1 activity (22,23), we 
found that metformin treatment led to a 
reduction in respiration in control hepatocytes, 
which was accentuated in AMPK-deficient 
hepatocytes (Fig. 3C). These results 
demonstrate the protective role of AMPK in 
maintaining hepatic energy homeostasis in 
response to a metabolic challenge induced by a 
reduction in cellular energy charge. 
 
Metabolic stress-induced AMPK activation is 
strengthened in hepatocytes incubated under 
simulated fasting conditions 
Given the modulation of AMPK activity 
during the fasting/refeeding and 
suckling/weaning transitions, we hypothesized 
that the regulation of hepatic AMPK is driven 
by changes in glucose availability and/or 
glucagon or insulin-stimulated changes in the 
kinase phosphorylation status (15,17,18). We 
thus treated mouse primary hepatocytes with 
the AMPK activators, metformin, AICAR, or 
A-769662, under various nutritional and 
hormonal conditions mimicking the fasting or 
fed states to identify the nature of the stimuli 
that modulate hepatic AMPK activity. 
Under low glucose/basal conditions (5 mM 
glucose), metformin induced the 
phosphorylation of AMPK at !-Thr172 and 
that of its downstream targets ACC at Ser79 
and Raptor at Ser792 in concentration- 
dependent manner (Fig. 4). Incubation of 
hepatocytes with high glucose concentrations 
(25 mM glucose) and insulin, to mimic 
feeding, increased the phosphorylation of Akt 
at Ser473 but did not alter metformin-induced 
AMPK phosphorylation relative to that of the 
basal condition (Fig. 4). In contrast, culturing 
the hepatocytes in a medium that simulated 
fasting conditions, which contained glucagon 
and in which glucose was replaced with lactate 
and pyruvate, robustly enhanced metformin-
induced AMPK phosphorylation 
concomitantly with an increase in the PKA 
substrate phosphorylation pattern (Fig. 4). 
 
Metabolic stress-induced energy depletion is 
worsened in AMPK-deficient hepatocytes 
incubated under simulated fasting conditions 
We next assessed the effect of changes in 
glucose concentrations and pancreatic hormone 
levels in culture medium on metformin-
induced energy depletion in both control and 
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AMPK-deficient hepatocytes. In the absence of 
metformin, the cellular energy charge was 
similar between control and AMPK-deficient 
hepatocytes and was not altered after an 8-h 
incubation under conditions mimicking fasting 
(glucose-free medium containing lactate and 
pyruvate plus glucagon) or refeeding (25 mM 
glucose plus insulin), indicating that these 
conditions are insufficient to alter the cellular 
energy state (Fig. 5A and 5B). Metformin 
treatment strongly correlated with a marked 
decrease in ATP and energy charge in both 
control and AMPK-deficient hepatocytes. As 
observed in the liver (Fig. 3A and 3B), the 
decrease in ATP levels and energy charge in 
response to metformin was greater in AMPK-
deficient hepatocytes than control hepatocytes 
(Fig. 5A and 5B). Metformin-induced energy 
depletion was also greater when hepatocytes 
were incubated under fasting-like than 
refeeding-like conditions, and this effect was 
greater in AMPK-deficient hepatocytes than 
control hepatocytes. Thus, the higher 
activation of AMPK in response to an energy 
stress in hepatocytes incubated under fasting-
like conditions coincides with a greater cellular 
energy deficiency. Moreover, the aggravation 
of energy depletion observed in AMPK-
deficient hepatocytes incubated under fasting 
conditions is consistent with the role of AMPK 
in regulating the cellular energy balance to 
restore cellular ATP levels to normal values. 
 
Glucose availability, but not pancreatic 
hormones, sensitizes AMPK activation during 
metabolic stress in hepatocytes 
To dissociate the impact of glucagon and 
insulin signaling from that of glucose 
availability on AMPK activity, we separately 
examined their respective effects on 
metformin-induced AMPK activation in 
hepatocytes. In the presence of 5 mM glucose, 
treatment with glucagon or insulin induced 
sustained phosphorylation of PKA-substrates 
or Akt-Ser473, respectively, but they had no 
effect on the pattern of change of AMPK 
phosphorylation at !-Thr172 or that of its 
downstream targets (ACC at Ser79 and Raptor 
at Ser792) induced by metformin (Fig. 6A). 
Conversely, the incubation of hepatocytes in 
glucose-free medium containing lactate and 
pyruvate led to greater metformin-induced 
AMPK phosphorylation than that in 
hepatocytes incubated with 5 or 25 mM 
glucose for 8 h (Fig. 6B). We obtained similar 
results with A-769662, a direct small molecule 
AMPK activator (Fig. S1). Furthermore, 
AMPK and ACC phosphorylation induced by 
the cell-permeable AMPK activator AICAR 
was unaltered by treatment with the pancreatic 
hormones glucagon or insulin (Fig. 7A). In 
contrast, a comparison of the action of AICAR 
at various glucose concentrations showed 
AMPK phosphorylation to be stimulated to a 
greater extent in glucose-free medium 
containing lactate and pyruvate plus glucagon 
than medium containing only 5 mM glucose or 
25 mM glucose plus insulin (Fig. 7B). In 
summary, AMPK activation in hepatocytes is 
enhanced by the scarcity of glucose, whereas 
changes in insulin or glucagon concentrations 
do not affect its activity. 
 
Switching to a glucose-free medium 
containing lactate and pyruvate transiently 
activates AMPK in hepatocytes 
In the previous experiments (Fig. 4, 6, 7 
and S1), we observed no changes in AMPK-!-
Thr172 phosphorylation after the incubation of 
hepatocytes for 8 h with various glucose 
concentrations in the absence of activators 
(metformin, AICAR or A-769662), This 
observation is consistent with the lack of an 
effect on the cellular energy state (Fig. 5). We 
tested whether changes in glucose availability 
could activate AMPK at early time points. 
Incubation of hepatocytes with a glucose-free 
medium containing lactate and pyruvate 
transiently activated AMPK signaling within 2 
h (Fig. 8A). Indeed, phosphorylation of !-
Thr172-AMPK and its downstream targets 
ACC and Raptor were maximal at 2 h and 
nearly returned to basal levels after 8 h (Fig. 
8A). In contrast, incubation in a medium 
containing 5 or 25 mM glucose did not modify 
AMPK signaling (Fig. 8A). Moreover, AMPK 
activation induced by the absence of glucose in 
the culture medium correlated with a low but 
significant decrease in intracellular ATP levels 
at 2 h, which was amplified in AMPK-
deficient hepatocytes (Fig. 8B). These results 
indicate that the lack of glucose induces 
transient activation of AMPK, which acts to 
adapt hepatocyte metabolism and maintain 
cellular energy levels. 
We next assessed AMPK activation in 
response to various activators at early time 
points in hepatocytes incubated with various 
levels of glucose. Activation of AMPK by 
metformin (Fig. 9) or AICAR (Fig. S2A) was 
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enhanced when hepatocytes were incubated in 
glucose-free medium containing lactate and 
pyruvate or with low glucose concentrations (5 
mM glucose). Similarly, incubation of 
hepatocytes with the direct small molecule 
activator A-769662 induced more pronounced 
ACC and Raptor phosphorylation in glucose-
free medium containing lactate and pyruvate 
(Fig. S2B). Unexpectedly, A-769662-mediated 
AMPK phosphorylation was only induced in 
the absence of glucose (Fig. S2B). 
 
Phosphorylation of AMPK! on the 
Ser485/491 residue does not alter its activity 
in hepatocytes 
Insulin and agents that elevate cellular 
cAMP have been reported to inhibit AMPK 
activity through the phosphorylation of 
AMPK! at Ser485/491 by Akt and PKA, 
respectively (20,24). We found that both 
insulin and glucagon weakly induced AMPK 
phosphorylation at !-Ser485/491 in primary 
hepatocytes. In contrast, AICAR induced 
massive phosphorylation at this site, likely 
resulting from autophosphorylation, as 
previously described (24). However, AMPK 
activity was not attenuated by increased !-
Ser485/491 phosphorylation, as shown by 
maintenance of the phosphorylation of its 
downstream target ACC (Fig. 7A and 7B), 
indicating the absence of an inhibitory effect of 
Ser485/491 phosphorylation on AMPK 
activation in primary hepatocytes. 
 
Discussion 
 
Over the past decade, the fuel-sensing 
enzyme AMPK has attracted much attention 
because of the associations drawn between the 
wide range of its metabolic downstream 
targets, including fatty-acid synthesis and 
oxidation, mitochondrial function, oxidative 
stress, inflammation, and autophagy and the 
alteration of these pathways by insulin 
resistance and metabolic syndrome-associated 
disorders (25). Although there is no clear 
evidence that polymorphisms in genes 
encoding AMPK subunits influence the 
occurrence of metabolic syndrome (26-28), a 
sustained decrease in AMPK activity has been 
found in the liver, skeletal muscle, and adipose 
tissue from obese or hyperglycemic rodents 
and humans in association with insulin 
resistance (29-33). Nevertheless, we have 
shown that liver-specific AMPK deficient mice 
display normal hepatic glucose and lipid 
homeostasis and are not prone to insulin 
resistance, suggesting that the decrease in 
AMPK activity associated with insulin 
resistance may be a consequence, rather than a 
cause, of changes in hepatic metabolism (10). 
By contrast, we and others have shown that 
reversible and physiological variation of 
hepatic AMPK activity occurs during the 
fasting-refeeding and suckling-weaning 
transitions (13-16) (Fig. 1). These changes in 
AMPK activity may account for the shift in 
hepatic lipid metabolism from catabolism to 
anabolism. However, the catabolic and/or 
anabolic stimuli responsible for the 
physiological modulation of AMPK activity 
during fasting are still poorly understood. It 
has been hypothesized that acute changes in 
hepatic AMPK activity are due to fluctuations 
in plasma levels of insulin and the counter 
regulatory action of glucagon (34). Indeed, 
conditions associated with increased glucagon 
activate AMPK, possibly through modulation 
of the hepatic energy charge (increase in the 
AMP/ATP ratio) and PKA-induced activation 
of LKB1 (18,35). Conversely, insulin has been 
reported to decrease AMPK activity through 
the phosphorylation of AMPK! at !1-
Ser485/!2-Ser491, with a concomitant loss of 
both AMPK!-Thr172 and ACC-Ser79 
phosphorylation (17,36). 
The role of the phosphorylation at 
Ser485/491 is not well understood and it is still 
unclear whether this phosphorylation 
contributes to enzyme regulation and AMPK 
activity. Interestingly, mutation of the Ser485 
residue to mimic phosphorylation by 
introduction of an aspartate residue in the 
AMPK!1 subunit is not sufficient to inhibit 
AMPK activation by liver purified AMPK 
kinase (37). Although phosphorylation at 
Ser485/491 has been shown to correlate with 
the inhibition of AMPK activity in a variety of 
tissues, we show that increased 
phosphorylation at this site is proportional to 
the increase in the phosphorylation of the 
downstream AMPK target ACC-Ser79 in 
primary hepatocytes (Fig. 7). Similarly, 
HepG2 cells treated with troglitazone showed 
an increase in phosphorylation of AMPK! at 
both Thr172 and Ser485 residues, associated 
with an increase in ACC-Ser79 
phosphorylation (38). This is also reminiscent 
of the effect of acute renal ischemia causing 
simultaneous phosphorylation of AMPK!-
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Thr172 and AMPK!-Ser485 in the kidney 
(39). Furthermore, despite that glucagon and 
insulin pretreatments induce phosphorylation 
at !-Ser485/491, this is not sufficient to reduce 
the phosphorylation of the activation loop !-
Thr172 in response to AICAR (Fig. 7). It is 
likely that the increase in Ser485/491 
phosphorylation reflects an 
autophosphorylation event, concomitant with 
the increase in AMPK activation, as previously 
demonstrated (24). It was suggested that 
phosphorylation of AMPK at this specific site 
may represent a regulatory mechanism to 
prevent over-stimulation of AMPK, in addition 
to potential cross-talk with inhibitory signaling 
pathways (24). Thus, further studies will be 
required to better understand the physiological 
impact of such phosphorylation on hepatic 
metabolism. 
We and others have shown that AMPK 
activation in the liver during fasting results 
from an increase in AMP/ATP and ADP/ATP 
ratios (40,41) (Fig. 2). However, the nature of 
the stimuli altering the AMP/ATP and 
ADP/ATP ratios and subsequent AMPK 
activity in the liver is somewhat unclear. Our 
results suggest that nutritional changes (i.e., 
glucose availability) rather than related 
hormonal changes (i.e., glucagon/ insulin ratio) 
likely underly the sensitization of AMPK to 
energetic stress induced by the dietary 
transition that takes place during fasting. 
Recent studies suggest that starvation-
induced AMPK!-Thr172 phosphorylation in 
the liver requires the formation of a ternary 
complex between axin, LKB1, and AMPK 
(16). Interestingly, AMP binding to AMPK has 
been shown to enhance its binding to the axin-
LKB1 complex and thus promote axin-
dependent AMPK!-Thr172 phosphorylation 
(7,16). Also, it has been reported that AMPK 
can sense glucose starvation independently of 
changes in adenine nucleotide concentrations 
through the formation of a lysosomal complex 
(42). Although we were unable to detect 
activation of AMPK in primary mouse 
hepatocytes incubated in glucose-free medium 
containing lactate and pyruvate for 8 h, we 
observed transient AMPK activation within 2 
h, associated with a decrease in cellular ATP 
levels (Fig. 8). Such transient activation of 
AMPK observed in hepatocytes after switching 
from glucose to lactate and pyruvate (Fig. 8) 
can be seen as a counter signal to adapt the 
metabolism to glucose starvation and maintain 
the cellular energy charge. Of note, transient 
AMPK activation induced by glucose 
starvation was low compared to drug-induced 
AMPK activation (Fig. 9 and Fig. S2), 
suggesting that substitution of glucose by 
lactate and pyruvate in medium had a 
relatively low impact on cellular energy levels. 
Furthermore, consistent with its role as an 
energy sensor acting to restore energy 
homeostasis, primary hepatocytes incubated in 
the absence of glucose (but incubated with 
lactate and pyruvate) exhibited enhanced 
activation of AMPK and amplified energy 
depletion in response to metformin-induced 
energy stress relative to that of hepatocytes 
incubated with glucose (5 or 25 mM) (Fig. 4, 
5, 6 and 9). Such an enhanced response to 
energy stress observed in the context of low 
glucose availability may be attributable to 
lower ATP generation due to an overall 
decrease in the glycolytic flux.  
Unexpectedly, we showed that the 
stimulation of AMPK signaling by the small 
molecule A-769662 was enhanced by low 
glucose levels and that AMPK!-Thr172 
phosphorylation was transiently induced under 
conditions of glucose starvation (Fig. S1 and 
S2). These effects appear to be paradoxical 
since A-769662 causes activation of AMPK 
independently of !-Thr172 phosphorylation 
via an allosteric mechanism and without 
compromising the cellular AMP/ATP ratio 
(43-45). Nevertheless, we have previously 
shown that AMP-induced phosphorylation of 
AMPK is enhanced by A-769662 (10,44). 
Thus, the AMPK-!-Thr172 phosphorylation 
observed with A-769662 in glucose-free 
medium can be interpreted as a synergic effect 
resulting from AMPK-!-Thr172 
phosphorylation caused by a transient increase 
in cellular AMP levels in response to glucose 
starvation and A-769662-binding to the AMPK 
complex. 
ATP depletion was more pronounced in the 
livers of hepatic AMPK-deficient mice treated 
with metformin than in those of control mice 
(Fig. 3). Similarly, ATP levels in primary 
AMPK-deficient hepatocytes were much lower 
than in control hepatocytes following 
incubation with metformin (Fig. 5), as 
previously reported (44). The depletion of 
hepatic ATP observed during fasting has also 
been shown to be amplified in the livers of 
AMPK-deficient mice (41). This exacerbated 
decrease in ATP levels in response to an 
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energy stress reveals metabolic inflexibility in 
AMPK-deficient hepatocytes and emphasizes 
the importance of AMPK in the maintenance 
of the hepatic energy charge through the 
control of adaptive mitochondrial function (46-
49). Of note, in the absence of energy stress, 
ATP levels in the livers and primary 
hepatocytes from AMPK-deficient mice are no 
different than those of the control counterparts, 
reinforcing the notion that hepatic AMPK is 
activated only during times of energy stress to 
maintain the energy balance. These results 
demonstrate that AMPK activation is crucial 
for maintaining energy homeostasis in the liver 
during the metabolic transition that occurs 
during fasting. 
AMPK has a high therapeutic potential for 
the management of dysregulated metabolism in 
the liver. Notably, pharmacological AMPK 
activation has shown beneficial effects in the 
treatment of liver steatosis (10,43,50,51). We 
have shown that drug-induced AMPK 
activation decreases hepatic lipid 
accumulation, both by inhibiting lipid 
synthesis and by stimulating fatty-acid 
oxidation (10). Thus, the modulation of hepatic 
AMPK activity by the nutritional state may 
have implications in future clinical practice. 
Indeed, our findings predict that hepatic 
AMPK activation in response to the 
administration of an AMPK-activating drug 
may be enhanced during fasting. On the other 
hand, postprandial delivery of an AMPK-
activating compound may counteract the 
lowing of hepatic AMPK activity due to the 
massive influx of glucose into liver after the 
ingestion of a carbohydrate-rich meal. In both 
conditions, the nutritional state may influence 
the downstream effects of AMPK. In the 
fasting state, AMPK-induced fatty-acid 
oxidation will be boosted. In the fed state, lipid 
synthesis from glucose will be inhibited by 
drug-induced AMPK activation. Consequently, 
the delivery of future AMPK activating 
therapies will need to consider the nutritional 
state and diet composition (low- or high-
carbohydrate) to adapt the dosage. 
In summary, our studies support the notion 
that reversible AMPK activation observed in 
the liver during nutritional transition (typically 
during fasting) results in a decrease in cellular 
energy charge, which is modulated by glucose 
availability rather changes in pancreatic 
hormone levels. In this context, AMPK 
activation is critical to preserve the cellular 
energy state in the liver by promoting a 
metabolic switch from the utilization of 
glucose to that of other substrates, notably, 
fatty acids, to supply energy needs. 
 
Experimental procedures 
 
Reagents and antibodies 
Metformin (#D5035) and glucagon were 
purchased from Sigma. AICAR was purchased 
from Toronto Research Chemicals. A-769662 
was kindly provided by Dr. Anudharan 
Balendran (Astra Zeneca). Human insulin 
(Actrapid) was purchased from Novo Nordisk. 
Primary antibodies directed against total 
AMPK" (#2532), AMPK" phosphorylated at 
Thr172 (#2531), phospho-AMPK!1(Ser485)/ 
AMPK!2(Ser491) (#4185), total acetyl-CoA 
carboxylase (ACC) (#3676), ACC 
phosphorylated at Ser79 (#3661), total Raptor 
(#2280), Raptor phosphorylated at Ser792 
(#2083), total Akt (#9272), Akt 
phosphorylated at Ser473 (#4058), and 
phospho-PKA substrate (#9624) were all 
purchased from Cell Signaling Technology. 
HRP-conjugated secondary antibodies were 
purchased from Calbiochem. All other 
materials unless otherwise indicated were 
purchased from Sigma. 
 
Animals 
Animal studies were approved by the Paris 
Descartes University ethics committee (no. 
CEEA34.BV.157.12) and performed under 
French authorization to experiment on 
vertebrates (no.75-886) in accordance with the 
European guidelines. C57BL/6J mice were 
obtained from Harlan France. Liver-specific 
double knockout of AMPK!1 and AMPK!2 
catalytic subunits was achieved by crossing 
AMPK!1lox/lox mice with AMPK!2lox/lox mice 
and then crossing the progeny with Alfp-Cre 
transgenic mice to generate AMPK!1lox/lox, 
!2lox/lox (control) and AMPK!1lox/lox, !2lox/lox-
Alfp-Cre (liver AMPK!1/!2 KO) mice (10). 
All mice were maintained in a barrier facility 
under a 12/12-h light/dark cycle with free 
access to water and standard mouse diet (in 
terms of energy: 65% carbohydrate, 11% fat, 
24% protein). 
 
Suckling and weaned rats 
Litters of 13-day-old Wistar rats with their 
mother were obtained from Janvier France. 
Litters were housed in individual cages under a 
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12/12-h light/dark cycle in a temperature-
controlled environment with free access to 
water and standard diet. When the pups were 
18 and 19 days of age, the mothers were fed 
separately from their offspring from 9:00 to 
12:00 a.m. and 4:00 to 7:00 p.m. to avoid early 
weaning of the pups. Twenty-day-old suckling 
pups were separated from their mother for 3 h 
to allow gastric emptying. Then, rats were 
force-weaned by gavage with 5 g/kg glucose or 
replaced with their mother. After 3 h, rats were 
sacrificed by decapitation. Blood was quickly 
collected, and the liver was immediately 
removed and frozen in liquid nitrogen in < 25 
s. Livers were stored at -80°C until analysis. 
After sacrifice, the stomachs of suckling pups 
were checked to ensure that they were filled 
with milk. 
 
Fasting and refeeding experiments 
For the fasting-refeeding experiments, mice 
were fasted for 24 h or fasted for 24 h and then 
refed a high-carbohydrate diet (70% 
carbohydrate in terms of total kcal with 64% 
sucrose in terms of weight, Harlan TD.08247) 
for 3 h. At the end of the refeeding period, 
mice were sacrificed by cervical dislocation 
and the liver immediately removed and frozen 
in liquid nitrogen in < 25 s. Livers were stored 
at -80°C until analysis. 
 
Blood glucose and plasma pancreatic 
hormone measurement 
Blood glucose concentrations were 
determined from blood isolated from the tail 
vein with a glucometer (Roche Diagnostics). 
Blood was collected into heparin-containing 
tubes and centrifuged to obtain plasma. Plasma 
insulin and glucagon levels were determined 
using mouse or rat ELISA kits (Crystal Chem). 
 
In vivo metformin treatment 
Ten-week-old control and liver 
AMPK!1/!2 KO mice in a fed state were 
injected intraperitoneally with saline or 200 
mg/kg metformin to induce a hepatic energy 
stress. Mice were sacrificed by cervical 
dislocation 1 h after metformin administration 
and the liver extracted and frozen in liquid 
nitrogen in < 25 s. Livers were stored at -80°C 
until adenine nucleotide analysis. 
 
Mouse primary hepatocytes 
Mouse primary hepatocytes were isolated 
from 10-12-week-old male mice using a 
modified version of the collagenase method as 
described previously (44). The cells were 
plated in M199 medium with Glutamax 
supplemented with 100 U/ml penicillin, 100 
$g/ml streptomycin, 10% (v/v) FBS, 500 nM 
dexamethasone (Sigma), 100 nM 
triiodothyronine (Sigma), and 10 nM insulin 
(Actrapid, Novo Nordisk) at a density of 4 x 
105 cells/well in six-well plates or 1 x 106 
cells/60-mm-diameter cell culture plate. After 
attachment (3 to 4 h), hepatocytes were 
maintained in M199 medium with antibiotics 
and 100 nM dexamethasone for 16 h. The cells 
were then stimulated with the respective 
compounds or hormones for the times 
indicated in the figure legends in glucose-free 
DMEM medium supplemented with 100 nM 
dexamethasone and lactate/pyruvate (10:1 
mM) or glucose (5 or 25 mM). 
 
Hepatocyte oxygen consumption assay 
Primary mouse hepatocytes were plated 
onto collagen I-coated Seahorse 96-well plates 
at a density of 10,000 cells/well. After 4 h, 
primary hepatocytes were cultured for 16 h in 
M199 medium containing antibiotics and 100 
nM dexamethasone. Hepatocytes were then 
switched to glucose-free DMEM supplemented 
with lactate/pyruvate (10:1 mM) and 100 nM 
dexamethasone 1 h prior to measuring 
respiration. The oxygen consumption rate 
(OCR, mitochondrial respiration) was 
monitored using the Seahorse Bioscience 
XF96 Extra Cellular Flux Analyzer in real 
time. The OCR was acquired under basal 
conditions and 15, 30, and 45 min after 
injection with 1 mM metformin. Results were 
normalized to total protein/well after 
completion of the assay and are expressed as 
pmoles O2 consumed per $g of protein per 
minute. 
 
Measurement of adenine nucleotide 
concentrations  
Adenine nucleotide concentrations were 
determined in cell extracts prepared from 
cultured hepatocytes or liver samples using an 
enzymatic method (44). Primary hepatocytes 
were treated as described in the figure legends, 
the culture medium removed, and cells on 60-
mm-diameter cell culture plates (1 x 106 
cells/plate) scraped into 200 $l 6% (v/v) ice-
cold HClO4 in < 5 s. For the liver, mice were 
treated as described in the figure legends. At 
the end of treatment, mice were sacrificed by 
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cervical dislocation and the livers extracted 
and frozen in liquid nitrogen in < 25 s. Two 
hundred milligrams of liver were homogenized 
in 1 ml 6% (v/v) ice-cold HClO4. Cell extracts 
were centrifuged at 10,000 g for 10 min at 4°C. 
The acid supernatant was neutralized and used 
for spectrophotometric determination of 
adenine nucleotides. Standard curves for ATP, 
ADP, and AMP were constructed with 25, 50, 
75, 100, 125, and 150 $M of each nucleotide. 
Determination of the adenine nucleotides 
presented in the Fig. 8B was performed by 
high-performance liquid chromatography as 
described previously (52). Adenine nucleotide 
levels are expressed in $mol/g of liver weight 
or nmol/mg of protein. The energy charge was 
calculated using the following equation: 
[ATP+ADP/2]/[ATP+ADP+AMP], where 
AMP, ADP, and ATP are the respective tissue 
concentrations (53). 
 
Western-blot analysis 
After the incubation times indicated in the 
figure legends, cultured hepatocytes were lysed 
in ice-cold lysis buffer containing 50 mM Tris, 
pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 10% glycerol, 50 
mM NaF, 5 mM sodium pyrophosphate, 1 mM 
Na3VO4, 25 mM sodium-!-glycerophosphate, 
1 mM DTT, 0.5 mM PMSF, and protease 
inhibitors (Complete Protease Inhibitor 
Cocktail; Roche). Lysates were sonicated on 
ice for 15 seconds to shear DNA and reduce 
viscosity. Pieces of liver were homogenized in 
ice-cold lysis buffer with a ball-bearing 
homogenizer (Retsch). The lysates and 
homogenates were centrifuged for 10 min at 
10,000 x g at 4°C and the supernatants 
removed for determination of total protein 
content with a BCA protein assay kit (Thermo 
Fisher Scientific). Fifty micrograms of protein 
from the supernatant was separated on 10% 
SDS-PAGE gels and transferred to 
nitrocellulose membranes. The membranes 
were blocked for 30 min at 37°C with Tris-
buffered saline supplemented with 0.05% 
NP40 and 5% nonfat dry milk. 
Immunoblotting was performed with the 
antibodies indicated in the figure legends, 
following standard procedures, and the signals 
detected by chemiluminescence reagents 
(Thermo). Total and phosphorylated AMPK, 
ACC, Raptor, and Akt were probed using 
separate membranes. X-ray films were scanned 
and band intensities were quantified by Image 
J (NIH) densitometry analysis. 
 
Statistical analysis 
Results are expressed as the means ± SD. 
Comparisons between groups were made by 
unpaired two-tailed Student’s t-tests or one-
way ANOVA, in conjunction with 
Bonferroni’s post hoc test for multiple 
comparisons, when appropriate, using 
GraphPad Prism 5.0 (GraphPad Software Inc.). 
Differences between groups were considered 
statistically significant when P < 0.05. 
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Figure 1 
 
Figure 1. Effect of suckling/weaning and fasting/refeeding transitions on AMPK activation in the liver. (A, 
B) Twenty-day-old suckling rats were separated from the mother for 3 h. They were then either force-weaned by 
gavage with 5 g/kg glucose (Weaned) or placed back with the mother (Suckling) for 3 h. (C, D) Ten-week-old 
C57BL6J mice were either fasted for 24 h (Fasted) or fasted for 24 h and then refed a high-carbohydrate diet 
(Refed) for 3 h. After nutritional manipulation, (A, C) blood glucose levels were determined, blood was 
collected to assess plasma insulin and glucagon levels (n = 10-12 per group), and (B, D) the livers were quickly 
collected for western-blot analysis using the indicated antibodies. Each lane represents the liver sample from an 
individual animal. Right panels represent the P-Thr172-AMPK!/AMPK! ratio from the quantification of 
immunoblot images (n = 5-6 per group). Data are presented as the means ± SD. ***P < 0.001 compared to refed 
mice or weaned rats.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of the fasting/refeeding transition on the energy state in the liver. Ten-week-old C57BL6J 
mice were either fasted for 24 h (Fasted) or fasted for 24 h and then refed a high-carbohydrate diet (Refed) for 3 
h. After nutritional manipulation, the livers were quickly collected to determine the ATP and ADP content and 
ADP/ATP ratios. Data are presented as the means ± SD. N = 10 per group. **P < 0.01, ***P < 0.001 compared to 
refed mice. 
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Figure 3 
 
 
 
Figure 3. Liver AMPK-deficient mice are more sensitive to hepatic energy stress. Ten-week-old control and 
liver AMPK!1/!2 KO mice (n = 7-8 per group) in the fed state were injected intraperitonaly with saline (Veh) or 
200 mg/kg metformin (Metf) to induce hepatic energy stress. After 1 h, livers were quickly collected as 
described in Experimental Procedures for hepatic ATP and ADP determination. (A) Liver ATP and ADP content 
and (B) ADP/ATP ratios are shown for each condition. Data are presented as the means ± SD. *P < 0.05, **P < 
0.01, ***P < 0.001 compared to vehicle-treated control or liver AMPK!1/!2 KO mice; §P < 0.05 compared to 
metformin-treated control mice. (C) Effect of metformin on respiration in control and AMPK!1/!2 KO 
hepatocytes. Control and AMPK!1/!2-deficient mouse primary hepatocytes plated in specialized microplates 
were switched to glucose-free medium supplemented with lactate and pyruvate (10:1 mM) and 100 nM 
dexamethasone 1 h prior to measuring respiration. The oxygen consumption rate (OCR, mitochondrial 
respiration) was monitored using the Seahorse Bioscience XF96 Extra Cellular Flux Analyzer in real time. The 
OCR was acquired under basal conditions and 15, 30, and 45 min after injection with 1 mM metformin. Results 
were normalized to total protein/well after completion of the assay. Results are representative of three 
independent experiments. Data are presented as the means ± SD. *P < 0.05 compared to basal conditions of 
control or AMPK!1/!2 KO hepatocytes; §P < 0.05 compared to control hepatocytes incubated under the same 
conditions.  
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Figure 4 
 
 
 
Figure 4. Effect of fasting-like and refeeding-like culture conditions on energy stress-induced AMPK 
activation in primary hepatocytes. Mouse primary hepatocytes were treated with various concentrations of 
metformin (0, 0.125, 0.25, 0.5, 1, or 2 mM) in glucose-free medium containing 10 mM lactate and 1 mM 
pyruvate plus 10 nM glucagon (L/P+Glucagon), which mimics the fasting state, in basal medium containing 5 
mM glucose alone (G5), or in refeeding-like medium containing 25 mM glucose plus 100 nM insulin 
(G25+insulin). After 8 h, cells were harvested for western-blot analysis. Immunoblots from hepatocyte lysates 
were performed using the indicated antibodies. The lower panel represents the P-Thr172-AMPK!/AMPK! ratio 
from the quantification of immunoblot images. Results are representative of three independent experiments. Data 
are presented as the means ± SD. ***P < 0.001 compared to G5 or G25+Insulin conditions. Hatched bars indicate 
an increase in the P-Thr172-AMPK!/AMPK! ratio in hepatocytes incubated in L/P+Glucagon relative to those 
incubated in G5 or G25+Insulin. 
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Figure 5 
 
 
Figure 5. Effect of fasting-like and refeeding-like culture conditions on energy depletion induced by a 
metformin-induced energy stress in control and AMPK-deficient hepatocytes. Control and AMPK!1/!2 KO 
mouse primary hepatocytes were treated with various concentrations of metformin (0, 0.125, 0.25, 0.5, 1, or 2 
mM) in glucose-free medium containing 10 mM lactate and 1 mM pyruvate plus 10 nM glucagon 
(L/P+Glucagon), which mimics the fasting state, in basal medium containing 5 mM glucose alone (G5), or in 
refeeding-like medium containing 25 mM glucose plus 100 nM insulin (G25+insulin). After 8 h, cells were 
harvested for measurement of the adenine nucleotide content. (A) Intracellular ATP content. (B) Adenylate 
energy charge in control and AMPK!1/!2 KO hepatocytes. Results are representative of three independent 
experiments. Data are presented as the means ± SD. *P < 0.05 compared to control or AMPK!1/!2 KO 
hepatocytes incubated without metformin; §P < 0.05 compared to control hepatocytes incubated under the same 
conditions; $P < 0.05 compared to AMPK!1/!2 KO hepatocytes incubated with the same metformin 
concentration in medium containing G25+Insulin.  
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Figure 6 
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Figure 6. Effect of glucose and pancreatic hormone levels on energy stress-induced AMPK activation in 
primary hepatocytes. Mouse primary hepatocytes were incubated with various concentrations of metformin (0, 
0.125, 0.25, 0.5, 1, or 2 mM) and under various culture conditions, including (A) 5 mM glucose plus 10 nM 
glucagon (G5+Glucagon), 5 mM glucose alone (G5), 5 mM glucose plus 100 nM insulin (G5+Insulin), (B) 
glucose-free medium containing 10 mM lactate and 1 mM pyruvate (L/P), 5 mM glucose alone (G5), or 25 mM 
glucose alone (G25). After 8 h, cells were harvested for western-blot analysis. Immunoblots from hepatocyte 
lysates were performed using the indicated antibodies. Lower panels represent the P-Thr172-AMPK!/AMPK! 
ratio from the quantification of immunoblot images. Results are representative of three independent experiments. 
Data are presented as the means ± SD. ***P < 0.001 compared to G5 or G25 conditions. Hatched bars indicate an 
increase in the P-Thr172-AMPK!/AMPK! ratio in hepatocytes incubated in L/P relative to those incubated in 
G5 or G25. 
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Figure 7. Effect of glucose and pancreatic hormone levels on AICAR-mediated AMPK activation in 
primary hepatocytes. Mouse primary hepatocytes were preincubated for 1 h under various culture conditions, 
including (A) 5 mM glucose (G5), 5 mM glucose plus 100 nM insulin, 5 mM glucose plus 100 nM glucagon, (B) 
10 mM lactate and 1 mM pyruvate without glucose (L/P) plus 10 nM glucagon, 5 mM glucose (G5), or 25 mM 
glucose (G25) plus 100 nM insulin and then various concentrations of AICAR (0, 50, 75, 100, or 200 $M) were 
added to the medium. After 8 h, cells were harvested for western-blot analysis. Immunoblots from hepatocyte 
lysates were performed using the indicated antibodies. Lower panels represent the P-Thr172-AMPK!/AMPK! 
ratio from the quantification of immunoblot images. Results are representative of three independent experiments. 
Data are presented as the means ± SD. **P < 0.01, ***P < 0.001 compared to G5 or G25 conditions. Hatched bars 
indicate an increase in the P-Thr172-AMPK!/AMPK! ratio in hepatocytes incubated in L/P relative to those 
incubated in G5 or G25. 
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Figure 8 
 
 
Figure 8. Time course of the effect of changing glucose levels on AMPK activity in primary hepatocytes. 
(A) Mouse primary hepatocytes were incubated under various culture conditions, including glucose-free medium 
containing 10 mM lactate and 1 mM pyruvate (L/P), 5 mM glucose (G5), or 25 mM glucose (G25). After 1, 2, 4 
or 8 h, cells were harvested for western-blot analysis. Immunoblots from hepatocyte lysates were performed 
using the indicated antibodies. The lower panel represents P-Thr172-AMPK!/AMPK! ratios from the 
quantification of immunoblot images. Results are representative of three independent experiments. Data are 
presented as the means ± SD. ***P < 0.001 compared to G5 or G25. Hatched bars indicate an increase in the P-
Thr172-AMPK!/AMPK! ratio in hepatocytes incubated in L/P relative to those incubated in G5 or G25. (B) 
Control and AMPK!1/!2 KO primary hepatocytes were incubated in glucose-free medium containing L/P or G5 
or G25. After 2 h, cells were harvested for the measurement of intracellular ATP content. Data are presented as 
the means ± SD. N = 6. *P < 0.05, L/P compared to G5 or G25. §P < 0.05, Control compared to AMPK!1/!2 KO 
hepatocytes incubated in L/P.  
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Figure 9 
 
 
 
 
 
 
 
Figure 9. Effect of glucose levels on the kinetics of metformin-mediated AMPK activation in primary 
hepatocytes. (A) Mouse primary hepatocytes were incubated without (Vehicle) or with 500 $M metformin 
under various culture conditions, including glucose-free medium containing 10 mM lactate and 1 mM pyruvate 
(L/P), 5 mM glucose (G5), or 25 mM glucose (G25). After 1, 2, 4, or 8 h, cells were harvested for western-blot 
analysis. Immunoblots from hepatocyte lysates were performed using the indicated antibodies. The lower panel 
represents the P-Thr172-AMPK!/AMPK! ratio from the quantification of immunoblot images. Data are 
presented as the means ± SD. n = 3. **P < 0.01, ***P < 0.001 compared to G5 or G25. Hatched bars indicate an 
increase in the P-Thr172-AMPK!/AMPK! ratio in hepatocytes incubated in L/P relative to those incubated in 
G5 or G25. 
   1 
 
Supplemental Figures 
 
 
 
 
Glucose availability but not changes in pancreatic hormones sensitizes 
hepatic AMPK activity during nutritional transition in rodents 
 
Camille Huet, Nadia Boudaba, Bruno Guigas, Benoit Viollet and Marc Foretz 
 
  
   2 
Figure S1 
 
 
 
 
 
 
 
 
 
 
Figure S1. Effect of glucose levels on A-769662-mediated AMPK activation in primary 
hepatocytes. Mouse primary hepatocytes were incubated with various concentrations of A-
762669 (0, 0.1, 0.3, 1, 3, or 10 !M) under various culture conditions, including glucose-free 
medium containing 10 mM lactate/1 mM pyruvate (L/P), 5 mM glucose (G5), or 25 mM 
glucose (G25). After 8 h, cells were harvested for western-blot analysis. Immunoblots from 
hepatocyte lysates were performed using the indicated antibodies. Presented blots are 
representative of two independent experiments. 
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Figure S2 
 
 
 
 
 
Figure S2. Effect of glucose levels on the kinetics of AICAR- and A-769662-mediated 
AMPK activation in primary hepatocytes. Mouse primary hepatocytes were incubated 
without (Vehicle) or with 100 !M AICAR (A) or 3 !M A-769662 (B) under various culture 
conditions, including glucose-free medium containing 10 mM lactate/1 mM pyruvate (L/P), 5 
mM glucose (G5), or 25 mM glucose (G25). After 1, 2, 4, or 8 h, cells were harvested for 
western-blot analysis. Immunoblots from hepatocyte lysates were performed using the 
indicated antibodies. Presented blots are representative of two independent experiments. 
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